A case of hepatitis associated with long-term use of Cimicifuga racemosa.

Cimicifuga racemosa and Hepatitis Alfredo Vannacci, MD, PhD, is a medical consultant at the Tuscan Regional Centre of Pharmacovigilance and a researcher in the Department of Preclinical and Clinical Pharmacology, Florence, Italy. Francesco Lapi, PharmD, PhD, is a research consultant at the Tuscan Regional Centre of Pharmacovigilance, a research fellow in the Department of Preclinical and Clinical Pharmacology, and a consultant to the Regional Agency of Healthcare Services of Tuscany, Epidemiology Unit, Florence. Eugenia Gallo, MS, and Michele Vietri, MS, PhD, are research fellows at both the Tuscan Regional Centre of Pharmacovigilance and in the Department of Preclinical and Clinical Pharmacology. Mario Toti, MD, is medical director in the Department of Infectious Diseases ASL9 Hospital, Grosseto, Italy. Roberto Raschetti, MD, is research director at the National Centre of Epidemiology, Surveillance and Health Promotion, National Institutes of Health, Rome, Italy. Fabio Firenzuoli, MD, is medical director at the Centre of Natural Medicine, ASL 11 Hospital, Empoli, Italy. Alessandro Mugelli, MS, MD, is a pharmacologist at the Tuscan Regional Centre of Pharmacovigilance and professor and chairman of the Department of Preclinical and Clinical Pharmacology. (Altern Ther Health Med. 2009;15(3):62-63.)